source
- STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on companyA Novartis drug for a rare neuromuscular condition failed in a key study, the company's second major trial collapse in a matter of days.STAT · 1h ago↗ source
- Novo Nordisk abandons two phase 3 trials of ziltivekimab, dimming blockbuster hopesNovo Nordisk announced it is terminating two late‑stage phase 3 studies of its IL‑6 ligand antibody ziltivekimab. The Hermes and Athena trials enrolled about 4,900 and 673 patients with heart fail…